Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

First Trust NYSE Arca Biotechnology Index Fund (FBT)

123.19
Delayed Data
As of Dec 15
 +1.91 / +1.57%
Today’s Change
90.56
Today|||52-Week Range
127.62
+35.55%
Year-to-Date

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

Performance

1 month+2.43% 3 years+7.73%
3 months-0.15% 5 years+21.97%
1 year+29.39% Since inception+17.27%
Data through 12/16/2017

Quote Details

Previous close$121.28
Open day’s range121.20 – 123.19
Net asset value (NAV)123.09 (12/15/2017)
Daily volume74,109
Average volume (3 months)53,454
Data as of 3:59pm ET, 12/15/2017

Peer Comparisonvs. Health ETFs

 FBTCategory
Performance 5-yr return+21.97%+16.79%
Expense Gross exp ratio0.56%1.33%
Risk 5 year sharpe ratio0.981.12
Net assets$1.2B$3.1B
Average market cap$11.0B$9.3B
Average P/E--21.7
Dividend / Share--0.30%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
NKTR Nektar Therapeutics7.44%
JUNO Juno Therapeutics Inc4.16%
NBIX Neurocrine Biosciences Inc4.05%
ALNY Alnylam Pharmaceuticals Inc3.91%
ILMN Illumina Inc3.64%
TECH Bio-Techne Corp3.61%
UTHR United Therapeutics Corp3.58%
GRFS Grifols SA3.50%
ALKS Alkermes Plc3.44%
IQV Iqvia Holdings Inc3.30%